Transkaryotic Therapies, Inc. (TKT) (TKTX) To Report Fourth Quarter And Year-End 2004 Financial Results On February 23, 2005 
10/19/2005 5:12:41 PM

CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. will announce its fourth quarter and year-end 2004 financial results on February 23, 2005 before the open of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on February 23, 2005 at 10:00 a.m. Eastern Time to discuss its fourth quarter and full year 2004 financial results and financial outlook for 2005.

Participants may access the call by dialing (913) 981-5533. This call will also be broadcast live over the Internet at under the Investor Information section. Please dial in 5 to 10 minutes prior to the scheduled conference call time or log on to the website at least 15 minutes prior to the call in order to register, download, and install any necessary software.

A replay of this conference call will be available for two weeks, beginning February 23, 2005 at 1:00 p.m. Eastern Time by dialing (719) 457- 0820 and using the access code 6847230. In addition, a replay of the webcast will be archived on the TKT website under Events in the Investor Information section.

About TKT

Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at

Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.

For More Information Contact: Daniella M. Lutz Corporate Communications Manager (617) 349-0205

Photo: NewsCom: Archive: Photo Desk, photodesk@prnewswire.comTranskaryotic Therapies, Inc.

CONTACT: Daniella M. Lutz, Corporate Communications Manager ofTranskaryotic Therapies, Inc., +1-617-349-0205